Rachel Klemovitch, Assistant Editor01.29.24
Shore Capital Partners announced it completed a partnership with C2Dx medical device company. Following the partnership the two companies have acquired Otolaryngology/Head and Neck Surgery (OHNS) products from Cook Medical.
The OHNS family of products provide minimally invasive procedures for ENT surgeons to help treat obstructive salivary disease, nasal/sinus and skull base reconstruction, dysphagia, and chronic eating disorders.
“Shore is very proud and excited to partner with C2Dx,” Shore partner and C2Dx Chairman of the Board Don Pierce told the press. “Kevin McLeod and his high caliber team have built an incredible company with an excellent reputation in the medical device space. We are well-positioned to build on their reputation as an industry leader through both acquisitions and organic growth, and the initial acquisition from Cook Medical complements and differentiates the platform’s product offerings.”
Since its founding in 2019, C2Dx has expanded its product offerings and capabilities through product line acquisitions and executive and employee recruitment.
OHNS is C2Dx’s fourth product line acquisition, having previously acquired the Shaw Scalpel from Hemostatix, and the STIC Intra-Compartmental Pressure Monitor and T/Pump Localized Temperature Therapy System from Stryker.
“We are ecstatic to announce our partnership with Shore Capital given their proven playbook for growth and track record of performance, specifically in the medical device space,” Mr. McLeod said. “Our partnership will enable us to invest further in our team, capabilities, and offerings, so we can grow faster and continue providing excellent service and products to our customers. Our acquisition of Cook’s OHNS product family is transformative for C2Dx, and consistent with the strategy we developed when we partnered with Shore.”
OHNS is C2Dx’s fourth product line acquisition, having previously acquired the Shaw Scalpel from Hemostatix, and the STIC Intra-Compartmental Pressure Monitor and T/Pump Localized Temperature Therapy System from Stryker.
“Cook has done an excellent job establishing these products as reliable, high-quality solutions for ENT and head & neck focused procedures specifically, and we have enjoyed working with them on this transaction,” said Mr. McLeod. “We are excited to increase the market penetration of these products through our deep and experienced sales organization, international distributor network, and product enhancements.”
The OHNS family of products provide minimally invasive procedures for ENT surgeons to help treat obstructive salivary disease, nasal/sinus and skull base reconstruction, dysphagia, and chronic eating disorders.
“Shore is very proud and excited to partner with C2Dx,” Shore partner and C2Dx Chairman of the Board Don Pierce told the press. “Kevin McLeod and his high caliber team have built an incredible company with an excellent reputation in the medical device space. We are well-positioned to build on their reputation as an industry leader through both acquisitions and organic growth, and the initial acquisition from Cook Medical complements and differentiates the platform’s product offerings.”
Since its founding in 2019, C2Dx has expanded its product offerings and capabilities through product line acquisitions and executive and employee recruitment.
OHNS is C2Dx’s fourth product line acquisition, having previously acquired the Shaw Scalpel from Hemostatix, and the STIC Intra-Compartmental Pressure Monitor and T/Pump Localized Temperature Therapy System from Stryker.
“We are ecstatic to announce our partnership with Shore Capital given their proven playbook for growth and track record of performance, specifically in the medical device space,” Mr. McLeod said. “Our partnership will enable us to invest further in our team, capabilities, and offerings, so we can grow faster and continue providing excellent service and products to our customers. Our acquisition of Cook’s OHNS product family is transformative for C2Dx, and consistent with the strategy we developed when we partnered with Shore.”
OHNS is C2Dx’s fourth product line acquisition, having previously acquired the Shaw Scalpel from Hemostatix, and the STIC Intra-Compartmental Pressure Monitor and T/Pump Localized Temperature Therapy System from Stryker.
“Cook has done an excellent job establishing these products as reliable, high-quality solutions for ENT and head & neck focused procedures specifically, and we have enjoyed working with them on this transaction,” said Mr. McLeod. “We are excited to increase the market penetration of these products through our deep and experienced sales organization, international distributor network, and product enhancements.”